Immunogenicity and pre-clinical efficacy of an OMV-based SARS-CoV-2 vaccine
The vaccination campaign against SARS-CoV-2 relies on the world-wide availability of effective vaccines, with a potential need of 20 billion vaccine doses to fully vaccinate the world population. To reach this goal, the manufacturing and logistic processes should be affordable to all countries, irrespectively of economical and climatic conditions. Outer membrane vesicles (OMV) are bacterial-derived vesicles that can be engineered to incorporate heterologous antigens. Given the inherent adjuvanticity, such modified OMV can be used as vaccine to induce potent immune responses against the associated protein. Here we show that OMVs engineered to incorporate peptides derived from the receptor binding motif (RBM) of the spike protein from SARS-CoV-2 elicit an effective immune response in vaccinated mice, resulting in the production of neutralizing antibodies (nAbs). The immunity induced by the vaccine is sufficient to protect the animals from intranasal challenge with SARS-CoV-2, preventing both virus replication in the lungs and the pathology associated with virus infection. Furthermore, we show that OMVs can be effectively decorated with the RBM of the Omicron BA.1 variant and that such engineered OMVs induced nAbs against Omicron BA.1 and BA.5, as judged by pseudovirus infectivity assay. Importantly, we show that the RBM438-509 ancestral-OMVs elicited antibodies which efficiently neutralized in vitro both the homologous ancestral strain, the Omicron BA.1 and BA.5 variants, suggesting its potential use as a pan SARS-CoV-2 vaccine. Altogether, given the convenience associated with ease of engineering, production and distribution, our results demonstrate that OMV-based SARS-CoV-2 vaccines can be a crucial addition to the vaccines currently available.
| Errataetall: |
UpdateIn: Vaccines (Basel). 2023 Sep 29;11(10):. - PMID 37896949 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2023 |
|---|---|
| Enthalten in: |
Research square - (2023) vom: 25. Mai |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Grandi, Alberto [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Revised 06.11.2023 published: Electronic UpdateIn: Vaccines (Basel). 2023 Sep 29;11(10):. - PMID 37896949 Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.21203/rs.3.rs-2788726/v1 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM357947452 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM357947452 | ||
| 003 | DE-627 | ||
| 005 | 20231226073708.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.21203/rs.3.rs-2788726/v1 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1193.xml |
| 035 | |a (DE-627)NLM357947452 | ||
| 035 | |a (NLM)37292970 | ||
| 035 | |a (PII)rs.3.rs-2788726 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Grandi, Alberto |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Immunogenicity and pre-clinical efficacy of an OMV-based SARS-CoV-2 vaccine |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 06.11.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a UpdateIn: Vaccines (Basel). 2023 Sep 29;11(10):. - PMID 37896949 | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a The vaccination campaign against SARS-CoV-2 relies on the world-wide availability of effective vaccines, with a potential need of 20 billion vaccine doses to fully vaccinate the world population. To reach this goal, the manufacturing and logistic processes should be affordable to all countries, irrespectively of economical and climatic conditions. Outer membrane vesicles (OMV) are bacterial-derived vesicles that can be engineered to incorporate heterologous antigens. Given the inherent adjuvanticity, such modified OMV can be used as vaccine to induce potent immune responses against the associated protein. Here we show that OMVs engineered to incorporate peptides derived from the receptor binding motif (RBM) of the spike protein from SARS-CoV-2 elicit an effective immune response in vaccinated mice, resulting in the production of neutralizing antibodies (nAbs). The immunity induced by the vaccine is sufficient to protect the animals from intranasal challenge with SARS-CoV-2, preventing both virus replication in the lungs and the pathology associated with virus infection. Furthermore, we show that OMVs can be effectively decorated with the RBM of the Omicron BA.1 variant and that such engineered OMVs induced nAbs against Omicron BA.1 and BA.5, as judged by pseudovirus infectivity assay. Importantly, we show that the RBM438-509 ancestral-OMVs elicited antibodies which efficiently neutralized in vitro both the homologous ancestral strain, the Omicron BA.1 and BA.5 variants, suggesting its potential use as a pan SARS-CoV-2 vaccine. Altogether, given the convenience associated with ease of engineering, production and distribution, our results demonstrate that OMV-based SARS-CoV-2 vaccines can be a crucial addition to the vaccines currently available | ||
| 650 | 4 | |a Preprint | |
| 700 | 1 | |a Tomasi, Michele |e verfasserin |4 aut | |
| 700 | 1 | |a Ullah, Irfan |e verfasserin |4 aut | |
| 700 | 1 | |a Bertelli, Cinzia |e verfasserin |4 aut | |
| 700 | 1 | |a Vanzo, Teresa |e verfasserin |4 aut | |
| 700 | 1 | |a Accordini, Silvia |e verfasserin |4 aut | |
| 700 | 1 | |a Gagliardi, Assunta |e verfasserin |4 aut | |
| 700 | 1 | |a Zanella, Ilaria |e verfasserin |4 aut | |
| 700 | 1 | |a Benedet, Mattia |e verfasserin |4 aut | |
| 700 | 1 | |a Corbellari, Riccardo |e verfasserin |4 aut | |
| 700 | 1 | |a Lascio, Gabriele Di |e verfasserin |4 aut | |
| 700 | 1 | |a Tamburini, Silvia |e verfasserin |4 aut | |
| 700 | 1 | |a Caproni, Elena |e verfasserin |4 aut | |
| 700 | 1 | |a Croia, Lorenzo |e verfasserin |4 aut | |
| 700 | 1 | |a Ravà, Micol |e verfasserin |4 aut | |
| 700 | 1 | |a Fumagalli, Valeria |e verfasserin |4 aut | |
| 700 | 1 | |a Lucia, Pietro Di |e verfasserin |4 aut | |
| 700 | 1 | |a Marotta, Davide |e verfasserin |4 aut | |
| 700 | 1 | |a Sala, Eleonora |e verfasserin |4 aut | |
| 700 | 1 | |a Iannacone, Matteo |e verfasserin |4 aut | |
| 700 | 1 | |a Kumar, Priti |e verfasserin |4 aut | |
| 700 | 1 | |a Mothes, Walther |e verfasserin |4 aut | |
| 700 | 1 | |a Uchil, Pradeep D |e verfasserin |4 aut | |
| 700 | 1 | |a Cherepanov, Peter |e verfasserin |4 aut | |
| 700 | 1 | |a Bolognesi, Martino |e verfasserin |4 aut | |
| 700 | 1 | |a Pizzato, Massimo |e verfasserin |4 aut | |
| 700 | 1 | |a Grandi, Guido |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Research square |d 2020 |g (2023) vom: 25. Mai |w (DE-627)NLM312780982 |7 nnns |
| 773 | 1 | 8 | |g year:2023 |g day:25 |g month:05 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.21203/rs.3.rs-2788726/v1 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2023 |b 25 |c 05 | ||